Comparative Pharmacology
Head-to-head clinical analysis: BETAMETHASONE DIPROPIONATE versus H CORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAMETHASONE DIPROPIONATE versus H CORT.
BETAMETHASONE DIPROPIONATE vs H-CORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Betamethasone dipropionate is a glucocorticoid receptor agonist that binds to cytosolic glucocorticoid receptors, leading to modulation of gene transcription. It suppresses pro-inflammatory cytokines (e.g., IL-1, IL-2, TNF-α), inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis, and stabilizes mast cells.
H-CORT (hydrocortisone) is a corticosteroid with glucocorticoid and mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Apply topically as 0.05% cream, ointment, or lotion to affected area once or twice daily. Maximum: 45 g/week.
Intravenous: 100-250 mg as a single dose or up to 1 gram daily for acute conditions. Oral: 20-30 mg daily in divided doses. Maintenance: 5-20 mg daily.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (parenteral); clinically, duration of adrenal suppression may extend beyond this.
Terminal elimination half-life: 1.5-2 hours. Clinical context: Short half-life requires q4-6h dosing; duration may be prolonged in hepatic impairment.
Renal, ~75% as conjugated metabolites; biliary/fecal, ~25%.
Renal: ~80% as metabolites, ~5% unchanged; biliary/fecal: ~15%
Category D/X
Category C
Corticosteroid
Corticosteroid